Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS)
Por:
Fernandez-Bobadilla, R, Martinez-Horta, S, Marin-Lahoz, J, Horta-Barba, A, Pagonabarraga, J, Kulisevsky, J
Publicada:
1 oct 2017
Resumen:
Introduction: The Parkinson's Disease-Cognitive Rating Scale (PD-CRS) is a valid and reliable instrument to screen for and diagnose mild cognitive impairment in PD (PD-MCI) and to monitor potential outcomes in clinical trials. Although this scale shows adequate sensitivity to change in non-demented PD patients, an alternative form (AF) with proven reliability could minimize practice effects associated with repeated testing.
Methods: We selected PD-CRS/AF items following the criteria proposed in the original PD-CRS. We assessed a prospective sample of 75 non-demented PD patients (normal cognition, n = 50; PD-MCI, n = 25) using both tools, administered on two consecutive days, in a randomized order.
Results: The PD-CRS/AF showed a high internal consistency (Cronbach's alpha = 0.80). Differences between total mean scores were not significant. Floor/ceiling effects were acceptable. The discriminative power for MCI was high for both tools (area under the curve 0.91; 95% CI, 0.84-0.98 for PD-CRS; 0.88, 95% CI, 0.80-0.96 for PD-CRS/AF). Receiver operating curve analysis showed the optimal cut-off point of the two versions to discriminate PD-MCI from PD-normal cognition was <= 81 (PD-CRS = sensitivity 94%, specificity 73%; PD-CRS/AF = sensitivity 92%, specificity 73%).
Conclusions: Our results suggest that the PD-CRS/AF is a valid and reliable instrument to complement the original PD-CRS as an analogous tool for serial cognitive testing for PD patients in clinical practice and cognitive trials. (c) 2017 Published by Elsevier Ld.
Filiaciones:
Fernandez-Bobadilla, R:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
IIB St Pau, Biomed Res Inst, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Barcelona, Spain
Ctr Neurol Navarra, Imarcoain, Navarra, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Martinez-Horta, S:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
IIB St Pau, Biomed Res Inst, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Barcelona, Spain
Marin-Lahoz, J:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
IIB St Pau, Biomed Res Inst, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Horta-Barba, A:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
IIB St Pau, Biomed Res Inst, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Barcelona, Spain
Pagonabarraga, J:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
IIB St Pau, Biomed Res Inst, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Barcelona, Spain
Kulisevsky, J:
Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
IIB St Pau, Biomed Res Inst, Barcelona, Spain
Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
|